Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2311 | Medical records-based recommendation Wiki | 1.00 |
| drug3744 | Standard of care therapies Wiki | 1.00 |
| drug3378 | Risk reduction Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012818 | Signs and Symptoms, Respiratory NIH | 0.50 |
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of the current study is to test different interventions to determine the most effective way to promote flu vaccine uptake in a high-risk population identified by an "artificial intelligence" (AI) or machine learning (ML) algorithm. The specific aims are: 1. Evaluate the effect on flu vaccination rates of informing health-system patients who are identified by an ML analysis of EHR data to be at high risk for flu complications that they are at high risk with either (a) no additional explanation, (b) an explanation that this determination comes from an analysis of their medical records, and (c) the additional explanation that an AI or ML algorithm made this determination. 2. Evaluate the effects of the same three interventions on diagnoses of flu in the same patients.
Description: Patient received a flu vaccination
Measure: Flu vaccination rate Time: Through the the end of the flu season (May 31st 2021), approximately 9 months assessment durationDescription: Patient received a flu diagnosis
Measure: Flu diagnosis rate Time: Through the the end of the flu season (May 31st 2021), approximately 9 months assessment durationDescription: Patient was diagnosed with flu-like symptoms
Measure: Flu-like symptoms rate Time: Through the the end of the flu season (May 31st 2021), approximately 9 months assessment durationDescription: Patient was diagnosed with flu-related complications
Measure: Flu complications rate Time: Through 3 months after the end of the flu season (August 31st 2021), approximately 12 months assessment durationDescription: Number of patient visits to the ER, examining relative rate of visits across Time 1 and 2
Measure: Change in ER visits from pre- to post-intervention Time: Within 12 months pre-intervention (Time 1) and within 12 months post-intervention (Time 2)Description: Number of patient hospital visits, examining relative rate of visits across Time 1 and 2
Measure: Change in hospitalizations from pre- to post-intervention Time: Within 12 months pre-intervention (Time 1) and within 12 months post-intervention (Time 2)Description: Non-targeted fellow household members of targeted patients received a flu vaccination
Measure: Flu vaccination among fellow household members Time: Through the the end of the flu season (May 31st 2021), approximately 9 months assessment durationDescription: Non-targeted fellow household members of targeted patients received a flu diagnosis
Measure: Flu diagnosis among fellow household members Time: Through the the end of the flu season (May 31st 2021), approximately 9 months assessment durationDescription: Non-targeted fellow household members of targeted patients were diagnosed with flu-like symptoms
Measure: Flu-like symptoms among fellow household members Time: Through the the end of the flu season (May 31st 2021), approximately 9 months assessment durationDescription: Non-targeted fellow household members of targeted patients were diagnosed with flu-related complications
Measure: Flu complications among fellow household members Time: Through 3 months after the end of the flu season (August 31st 2021), approximately 12 months assessment durationDescription: Non-targeted sub-threshold risk patients received a flu vaccination
Measure: Flu vaccination among those at sub-threshold risk Time: Through the the end of the flu season (May 31st 2021), approximately 9 months assessment durationDescription: Non-targeted sub-threshold risk patients received a flu diagnosis
Measure: Flu diagnosis among those at sub-threshold risk Time: Through the the end of the flu season (May 31st 2021), approximately 9 months assessment durationDescription: Non-targeted sub-threshold risk patients were diagnosed with flu-like symptoms
Measure: Flu-like symptoms among those at sub-threshold risk Time: Through the the end of the flu season (May 31st 2021), approximately 9 months assessment durationDescription: Non-targeted sub-threshold risk patients were diagnosed with flu-related complications
Measure: Flu complications among those at sub-threshold risk Time: Through 3 months after the end of the flu season (August 31st 2021), approximately 12 months assessment durationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports